Lupin has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its new injectable facility located in Nagpur, India. The EIR was issued post the last inspection of the facility conducted from October 17, 2022 to October 29, 2022.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.